146 related articles for article (PubMed ID: 1472260)
1. Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.
Danesi R; Bernardini N; Agen C; Costa M; Zaccaro L; Pieracci D; Malvaldi G; Del Tacca M
Cancer Chemother Pharmacol; 1992; 29(4):261-5. PubMed ID: 1472260
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin.
Danesi R; Bernardini N; Agen C; Costa M; Macchiarini P; Della Torre P; Del Tacca M
Toxicology; 1991; 70(2):243-53. PubMed ID: 1763418
[TBL] [Abstract][Full Text] [Related]
3. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin.
Pinna A; Agen C; Di Paolo A; Innocenti F; Nardini D; Danesi R; Del Tacca M
J Environ Pathol Toxicol Oncol; 1994; 13(1):25-31. PubMed ID: 7823290
[TBL] [Abstract][Full Text] [Related]
4. Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol.
Danesi R; Marchetti A; Bernardini N; La Rocca RV; Bevilacqua G; Del Tacca M
Cancer Chemother Pharmacol; 1990; 26(6):403-8. PubMed ID: 2171795
[TBL] [Abstract][Full Text] [Related]
5. 3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity.
Danesi R; Agen C; Grandi M; Nardini V; Bevilacqua G; Del Tacca M
Eur J Cancer; 1993; 29A(11):1560-5. PubMed ID: 8217363
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.
Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P
Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart.
Agen C; Sironi AM; Danesi R; Costa M; Bernardini N; Paparelli A; Della Torre P; Del Tacca M
Toxicology; 1992 Nov; 75(3):209-19. PubMed ID: 1455430
[TBL] [Abstract][Full Text] [Related]
8. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.
Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M
Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601
[TBL] [Abstract][Full Text] [Related]
9. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
Efentakis P; Varela A; Chavdoula E; Sigala F; Sanoudou D; Tenta R; Gioti K; Kostomitsopoulos N; Papapetropoulos A; Tasouli A; Farmakis D; Davos CH; Klinakis A; Suter T; Cokkinos DV; Iliodromitis EK; Wenzel P; Andreadou I
Cardiovasc Res; 2020 Mar; 116(3):576-591. PubMed ID: 31228183
[TBL] [Abstract][Full Text] [Related]
10. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats.
Danesi R; Bernardini N; Marchetti A; Bernardini M; Del Tacca M
Cancer Chemother Pharmacol; 1990; 25(5):326-32. PubMed ID: 2306792
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
Hirano S; Wakazono K; Agata N; Iguchi H; Tone H
Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387
[TBL] [Abstract][Full Text] [Related]
13. Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats.
Villani F; Galimberti M; Monti E; Piccinini F; Poggi P; Lanza E; Rozza A; Favalli L
Pharmacol Res; 1991 Feb; 23(2):195-202. PubMed ID: 2062794
[TBL] [Abstract][Full Text] [Related]
14. Preliminary evaluation of myocardial toxicity of 4'-deoxydoxorubicin: experimental and clinical results.
Villani F; Comazzi R; Genitoni V; Lacaita G; Guindani A; Crippa F; Monti E; Piccinini F; Rozza A; Lanza E
Drugs Exp Clin Res; 1985; 11(3):223-31. PubMed ID: 3836127
[TBL] [Abstract][Full Text] [Related]
15. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat.
Jensen RA; Acton EM; Peters JH
Cancer Res; 1984 Sep; 44(9):4030-9. PubMed ID: 6744318
[TBL] [Abstract][Full Text] [Related]
16. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein.
Andreadou I; Papaefthimiou M; Zira A; Constantinou M; Sigala F; Skaltsounis AL; Tsantili-Kakoulidou A; Iliodromitis EK; Kremastinos DT; Mikros E
NMR Biomed; 2009 Jul; 22(6):585-92. PubMed ID: 19308947
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects.
Jensen RA; Acton EM; Peters JH
J Cardiovasc Pharmacol; 1984; 6(1):186-200. PubMed ID: 6199603
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity and antitumor activity of a copper(II)-doxorubicin chelate.
Monti E; Paracchini L; Piccinini F; Malatesta V; Morazzoni F; Supino R
Cancer Chemother Pharmacol; 1990; 25(5):333-6. PubMed ID: 2155062
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of CardiPro against doxorubicin-induced cardiotoxicity in mice.
Mohan IK; Kumar KV; Naidu MU; Khan M; Sundaram C
Phytomedicine; 2006 Mar; 13(4):222-9. PubMed ID: 16492523
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat.
Jensen RA
J Pharmacol Exp Ther; 1986 Jan; 236(1):197-203. PubMed ID: 3941392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
